mCRPC progression of disease after [177Lu]Lu-PSMA-617 detected on [18F]Choline: a case of PCa heterogeneity

Riccardo Laudicella; Fabio Minutoli; Simona Russo; Massimiliano Siracusa; Michelangelo Bambaci; Benedetta Pagano; Sergio Baldari

doi:10.1016/j.eucr.2024.102750

mCRPC progression of disease after [¹⁷⁷Lu]Lu-PSMA-617 detected on [¹⁸F]Choline: a case of PCa heterogeneity

Urol Case Rep. 2024 May 8:54:102750. doi: 10.1016/j.eucr.2024.102750. eCollection 2024 May.

Authors

Riccardo Laudicella¹, Fabio Minutoli¹, Simona Russo¹, Massimiliano Siracusa¹, Michelangelo Bambaci², Benedetta Pagano¹, Sergio Baldari¹

Affiliations

¹ Nuclear Medicine Unit, Department of Biomedical and Dental Sciences and of Morpho-Functional Imaging, University of Messina, 98121, Italy.
² Nuclear Medicine Unit, Humanitas Istituto Clinico Catanese, Misterbianco, 95045, Italy.

Abstract

Radioligand therapy with [¹⁷⁷Lu]Lu-PSMA is a theranostic approach for heavily treated mCRPC patients with positive PSMA PET in the absence of relevant PSMA-negative metastases assessed through CT, MRI, bone scan or FDG PET. In this case, we described a mCRPC patient treated with RLT with discordant PSA values and PSMA images, in which Choline PET confirmed a biochemically suspected disease progression (PD), showing metastatic lesions not revealed by PSMA imaging.

Keywords: FDG; Metastatic castration-resistant prostate cancer; PRRT; RLT; Theranostics.

Publication types

Case Reports